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Abstract
Background: Platelets play a fundamental role in pathological events underlying acute coronary syndrome (ACS). Because
platelets do not have a nucleus, proteomics constitutes an optimal approach to follow platelet molecular events associated
with the onset of the acute episode.
Methodology/Principal Findings: We performed the first high-resolution two-dimensional gel electrophoresis-based
proteome analysis of circulating platelets from patients with non-ST segment elevation ACS (NSTE-ACS). Proteins were
identified by mass spectrometry and validations were by western blotting. Forty protein features (corresponding to 22
unique genes) were found to be differentially regulated between NSTE-ACS patients and matched controls with chronic
ischemic cardiopathy. The number of differences decreased at day 5 (28) and 6 months after the acute event (5).
Interestingly, a systems biology approach demonstrated that 16 of the 22 differentially regulated proteins identified are
interconnected as part of a common network related to cell assembly and organization and cell morphology, processes very
related to platelet activation. Indeed, 14 of those proteins are either signaling or cytoskeletal, and nine of them are known
to participate in platelet activation by aIIbb3 and/or GPVI receptors. Several of the proteins identified participate in platelet
activation through post-translational modifications, as shown here for ILK, Src and Talin. Interestingly, the platelet-secreted
glycoprotein SPARC was down-regulated in NSTE-ACS patients compared to stable controls, which is consistent with a
secretion process from activated platelets.
Conclusions/Significance: The present study provides novel information on platelet proteome changes associated with
platelet activation in NSTE-ACS, highlighting the presence of proteins involved in platelet signaling. This investigation paves
the way for future studies in the search for novel platelet-related biomarkers and drug targets in ACS.
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Introduction
Platelets play a fundamental role in the initiation, development
and total extent of myocardial damage in acute coronary syndrome
(ACS). The rupture of an unstable atherosclerotic plaque leads to
the local generation of thrombin and deposition of fibrin. This in
turn promotes platelet activation, adhesion and aggregation, and
the formation of intra-coronary thrombus [1,2]. Patients with
complete occlusion may manifest ST segment elevation myocardial
infarction (STEMI) if the lesion occludes an artery supplying a
substantial volume of myocardium, but the same occlusion in the
presence of extensive collateralization may manifest as a non-ST
segment elevation acute coronary syndrome (NSTE-ACS) [3].
In recent years proteomics has emerged as a novel technology
applied to cardiovascular research with the aim of identifying
novel biomarkers that could help to improve the diagnosis and
illuminate disease mechanisms [4,5]. In the context of ACS,
proteomics has been primarily applied to the study of plasma [6]
and monocytes [7] from ACS patients, leading to the identification
of some potential biomarkers. However, to the best of our
knowledge this is the first time high-resolution proteomics is
applied to the study of platelets in ACS.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13404Because platelets do not have a nucleus, proteomics is a perfect
tool to approach their biochemistry. In the last ten years proteomics
has been successfully applied to platelet research [8,9]. We have
been among the pioneers in the field, with a primary focus on
signaling studies [10–13]. Based on our previous experience, we
carried out a high-resolution two-dimensional gel electrophoresis(2-
DE)-based proteome analysis of platelets from NSTE-ACS patients
versus stable coronary artery disease (SCAD) controls. The objec-
tive was to identify, through a global proteomic approach,
differentially regulated platelet proteins that could provide infor-
mation on the molecular mechanisms playing a major role in the
unwanted platelet activation associated with the ACS.
Materials and Methods
Ethics Statement
The study was approved by the local Ethics Committee (Galician
Clinical Investigation Ethics Committee) and developed according
to the principles outlined in the Declaration of Helsinki. All patients
included in the study signed a written informed consent.
Patients
Eighteen patients admitted into a tertiary hospital from the
northwest of Spain presenting with NSTE-ACS, defined as angina
pain of at least 10 min duration with troponin elevation and/or ST-
T changes in the electrocardiogram, entered the study. Exclusion
criteria were inflammatory or neoplastic diseases, coagulation
disorders,platelet-associateddisorders,othersignificantheartdisease
except left ventricular hypertrophy secondary to hypertension,
chronic drug therapy (except for drugs required to treat pre-existing
clinical atherosclerosis or its risk factors), and having suffered from
surgical procedures, major traumatisms, thromboembolic events or
revascularization procedures in the previous 3 months.
At the moment of diagnosis, the patients were asked to
participate in the study. In case of acceptance, they signed the
informed consent, and 27 mL of blood were collected in sodium
citrate BD Vacutainer tubes for analysis. All samples were
obtained within the first 24 hours following the initiation of the
symptoms and immediately after arrival at the emergency
department. In most cases, patients were administered aspirin
before arrival to hospital, so aspirin-pretreated patients were
admitted in the study. Some patients had also clopidogrel
treatment and were also admitted. However, patients previously
treated with anti-aIIbb3 drugs were excluded. A second blood
sample was taken on day 5 to investigate if there was a fast
reversion of the changes observed in the platelet proteome on
admission. Another blood sample was taken after 6 months, as we
hypothesized that most changes observed on admission could be
normalized after that time since the status of the ACS patients
should be then closer to that of chronic controls. Blood was also
collected from 10 matched stable coronary artery disease patients
(SCAD), suffering from stable chronic ischemic cardiopathy. Such
a group was decided to be the most adequate control group due to
the clinical characteristics of the ACS patients. SCAD patients
were required not to have a history of acute cardiovascular event
within the year before the inclusion in the study.
Platelet isolation
Platelets were isolated by an established method that limits
contamination from other blood cells as described previously [14].
Washed platelets were resuspended in Tyrodes-HEPES (134 mM
NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3,
20 mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3) at 5610
8
platelets/ml, and incubated at room temperature for 30 min
(resting step). Five minutes before the end of the resting step,
EGTA was added to a final concentration of 1 mM to prevent
spontaneous aggregation during centrifugation [14]. Platelets were
thenspundownat10,000 gand,afteradditionof5 mLofaprotease
inhibitor cocktail (Sigma, St. Louis, MO, USA), immediately frozen
inliquidnitrogen fora few seconds followed bytheadditionof 2-DE
sample buffer (see below). Protein samples were stored at 280uC.
Surface expression of platelet aIIbb3
The determination of the platelet surface expression of aIIbb3
integrin was performed by flow cytometry using platelet-rich
plasma (PRP) aliquots and specific antibodies as indicated in
Supporting Information S1.
Two-dimensional gel electrophoresis
Protein quantitation was done with the Coomassie plus protein
reagent (Thermo Scientific, Asheville, NC). The amount of platelet
protein obtained from each patient was of 1450.66401.5 mg. Six-
hundred micrograms of protein were loaded onto each gel to allow
detection of low abundant proteins. The remaining protein was
used for western blotting and, when possible, preserved for
proteomics in case of unexpected technical problems (e.g. gel
breakage). Therefore, regarding the proteomic study, an individual
gel was run for each blood sample, from each patient, at three
different times: on admission, 5 days, and 6 months.
For each sample, protein was dissolved in 500 ml of 2D sample
buffer (5 M urea, 2 M thiourea, 2 mM tributyl-phosphine,
65 mM DTT, 65 mM CHAPS, 0.15 M NDSB-256, 1 mM
sodium vanadate, 0.1 mM sodium fluoride, and 1 mM benzami-
dine). Ampholytes (Servalyte 4–7) were added to the sample to a
final concentration of 1.6% (v/v). First dimension was on
immobilized pH gradient (IPG) strips 4–7, 24 cm (GE Health-
care). Second dimension was by SDS-polyacrylamide gel electro-
phoresis (PAGE) on 10% gels. Further information on the 2-DE
protocol can be found in Supporting Information S1.
Following electrophoresis, gels were fixed in 10% methanol/7%
acetic acid for 1 hour, and stained overnight with Sypro Ruby
fluorescent dye. After staining, gels were washed for 1 hour in
10% methanol/7% acetic acid, and scanned in a Typhoon 9410
(GE Healthcare).
Differential image analysis
Due to the high amount of images to be processed, images were
sent to the Ludesi Analysis Center (Lund, Sweden, http://www.
ludesi.com) for professional image analysis using Ludesi REDFIN
3 software. That allowed an optimal control over potential
technical variations. Spot detection, segmentation and matching
followed a strict protocol to ensure a high level of correctness. Gels
were matched by using all-to-all spot matching, avoiding the bias
caused by the use of a reference gel. The integrated intensity of
each of the spots was measured, and the background corrected
and normalized. Normalization removes systematic gel intensity
differences originating, for example, from variations in staining,
scanning time and protein loading by mathematically minimizing
the median expression difference between matched spots. This
allows a satisfactory quantification and comparison of different
gels. Differential expression of proteins was defined on the basis of
.1.5-fold change between group averages and p,0.05.
Mass spectrometric analysis
Protein features chosen for mass spectrometric analysis were excised
from the gels and manually in-gel digested with trypsin following the
protocol defined by Shevchenko [15]. Proteins were reduced with
Platelet Proteomics of ACS
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MS analysis,dried peptideswere dissolved in 4 mLo f0 . 5%f o r m i ca c i d .
Equal volumes (0.5 mL) of peptide and matrix solution, consisting of
3 mg alpha-cyano-4-hydroxycinnamic acid (a-CHCA) dissolved in
1 mL of 50% acetonitrile in 0.1% trifluoroacetic acid, were deposited
using the thin layer method, onto a 384 Opti-TOF MALDI plate
(Applied Biosystems). Mass spectrometric data were obtained in an
automated analysis loop using 4800 MALDI-TOF/TOF analyzer
(Applied Biosystems). MS spectra were acquired in reflectron positive-
ion mode with a Nd:YAG, 355 nm wavelength laser, averaging 1000
laser shots and using at least three trypsin autolysis peaks as internal
calibration. All MS/MS spectra were performed by selecting the
precursors with a relative resolution of 300 (FWHM) and metastable
suppression. Automated analysis ofm a s sd a t aw a sa c h i e v e db yu s i n g
the 4000 Series Explorer Software V3.5. MS and MS/MS spectra data
were combined through the GPS Explorer Software v3.6. Database
search was performed with the Mascot v2.1 search tool (Matrix
Science, London, UK) screening SwissProt (release 56.0). Searches
were restricted to human taxonomy allowing carbamidomethyl
cysteine as a fixed modification and oxidized methionine as potential
variable modification. Both the precursor mass tolerance and the MS/
MS tolerance were set at 30 ppm and 0.35 Da, respectively, allowing 1
missed tryptic cleavage site. All spectra and database results were
manually inspected in detail using the above software.
Western blotting
Western blot analyses were carried out on PVDF membranes
using the following primary antibodies and dilutions: mouse anti-
ILK (1:200), rabbit anti-Src (1:200) and rabbit anti-SPARC (1:500)
- all from Santa Cruz Biotechnology, Inc. (Delaware, CA, USA) -
and mouse anti-b-actin (1:1000) from Millipore (Temecula, CA,
USA). Membranes were exposed to horseradish peroxidase-
labelled goat anti-rabbit or goat anti-mouse antibodies (dilution
1:2000) (Pierce, Rockford, USA), processed using an enhanced-
chemiluminiscence system (ECL, Pierce, Rockford, USA) and
quantified by densitometry. Further details on the western blot
protocol can be found in Supporting Information S1.
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis software (Ingenuity Systems, CA)
was used to investigate possible interactions between all the
identified proteins. Interactive pathways were generated to observe
potential direct and indirect relations among the differentially
expressed proteins.
Statistical analysis
Data for categorical or dichotomous variables are expressed as
percentages and compared using Chi-squared test or Fisher’s exact
test. Data for continuous variables are expressed as the mean 6
standard deviation and compared by Mann-Whitney test. The
differential proteomic analysis was done analyzing all the spots
between patients with ACS and SCAD; for a given spot the p-
value was calculated using the quantified and normalized volumes
for the matched spot in each of the images.
All probability values were 2-tailed, and values of ,0.05 were
considered to indicate statistical significance. All analyses were
performed using SPSS 15.0 software for Windows (SPSS Inc.,
Tokyo, Japan).
Results
Baseline patients’ characteristics
Eighteen patients admitted to hospital with the diagnosis of
NSTE-ACS and ten age and gender-matched patients with stable
coronary artery disease were included in the study. There were
only few clinical differences between both groups as shown in
Table 1.
Almost all patients included in the acute group were high risk
patients, 53% having TIMI risk score $3, maximal Tn I levels
were of 5.166.1 ng/mL and maximal CPK-MB of 30.26
39.1 IU/L. Thirty-three per cent of acute patients presented ST
and/or T wave changes on the electrocardiogram and in 61% of
them these affected to more than four derivations. Almost 44% of
patients in the mentioned group presented with segmentary wall
motion abnormalities on echocardiography.
Platelets from NSTE-ACS patients express a characteristic
proteomic profile
As a control of the platelet functional status in each patient,
platelet surface expression levels of aIIbb3 were measured by flow
cytometry on PRP. As expected, all subjects displayed normal
values of both integrin subunits at the platelet surface, with no
significant differences among groups (not shown). Our standard-
ized experimental conditions for platelet isolation and protein
extraction resulted in reproducible high-resolution 2D gels
(24621 cm). In consequence, a mean of 22386112.9 protein
features were found on pI 4–7 gels corresponding to platelets from
SCAD patients, whereas 2298688.6 protein features were found
in the NSTE-ACS samples. We focused on the identification of
disappearing and appearing spots, as well as up- and down-
regulation of spot intensities where the fold change was at least 1.5
(with p,0.05). By applying these criteria, 40 protein features were
detected as differentially regulated when comparing the platelet
proteome of NSTE-ACS patients at admission versus SCAD
controls (Figure 1). All protein features were successfully identified
by mass spectrometry. They correspond to 22 different open
reading frames (ORFs) (Table 2 and Table S1). Ten of the protein
features identified were up-regulated in NSTE-ACS samples gels,
whereas 30 were down-regulated. Five proteins were represented
in the gels by more than one spot; for instance, talin-1 was present
in 10 spots. Further information on the 2-DE analysis can be
found in Supporting Information S2.
The number of proteins differentially regulated in platelets from
NSTE-ACS patients, as compared to stable controls, was
decreasing with time. As mentioned above, on admission the
number of differentially-regulated protein features was of 40
(Table 2). At day 5, that number was reduced to 28 proteins. After
6 months, only five protein spots remained significantly different
(Table S2 and Figure S1).
Functional groups identified: involvement of proteins
related to platelet activation
Attending to their function, the 22 platelet proteins differentially
regulated in NSTE-ACS compared to SCAD controls may be
classified in the following groups (see Table 2): cytoskeletal/
signaling (64%), vesicles/secretory trafficking pathway (18%),
extracellular function (9%), and miscellaneous (9%). A close-up
view of a selection of differentially regulated proteins, together
with their expression levels in controls and NSTE-ACS patients at
different time points, is shown in Figure 2.
Ingenuity Pathways Analysis software (Ingenuity Systems, CA)
was used to investigate possible interactions between all the
identified proteins in order to highlight predominant networks.
Interestingly, 16 of the 22 differentially regulated proteins
identified are interconnected as a part of a common network
related to cell assembly and organization and cell morphology
(Figure 3). Fourteen of those proteins are either signaling or
Platelet Proteomics of ACS
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platelet activation by aIIbb3 and/or GPVI receptors (Figure 3).
More precisely, eight of them play a relevant role in integrin
aIIbb3 signaling: a-actinin-1, ADAP (adhesion- and degranulation
promoting adapter protein) – also known as FYB or SLAP-130 -
and Src [12]; filamin-A [16], F-actin capping protein [17], zyxin
Table 1. Baseline characteristics of NSTE-ACS and SCAD patients.
Variable NSTE-ACS (n=18 patients) SCAD (n=10 patients)
Age (years) 66.4611.8 62.0613.0
Females (%) 33.3 20.0
Body Mass Index (kg/m
2) 29.163.6 27.062.7
Systolic Blood Pressure (mmHg) 139.3627.6 134.6615.6
Diastolic Blood Pressure (mmHg) 81.1618.6 81.8613.9
Heart Rate (bpm) 73.1610.5 74.2615.6
Hx Arterial Hypertension (%) 61.1 50.0
Hx Diabetes Mellitus (%) 22.2 30.0
Hx Smoking (%) 16.7 10.0
Hx Dyslipidemia (%)* 83.3 40.0
Hx Coronary Artery Disease (%)* 27.8 100
Hx Cerebro-vascular Disease (%) 16.7 10.0
Hx Congestive Heart Failure (%) 11.1 0
Hx Peripheral Artery Disease (%) 5.6 20.0
Laboratory Measurements
Hemoglobin (g/dl) 14.361.6 13.961.3
Leucocites/mL 9748.962887.9 8744.362030.9
Platelets/mL 228994.4672644.1 241828.66108296.5
Mean Platelet Volume (fL) 8.961.4 8.661.3
Platelets Distribution Width (%) 56.368.4 51.362.3
Glucose (mg/dl)* 129.0650.6 97.7613.2
Creatinin (mg/dl) 0.960.2 0.960.2
Proteins (mg/dl) 6.660.5 6.960.4
Cholesterol (mg/dl) 188.4630.3 151.1635.9
LDL-Cholesterol (mg/dl) 107.8636.3 91.6639.5
HDL-Cholesterol (mg/dl) 32.9616.5 36.866.7
Triglycerides (mg/dl) 180.16107.5 145.66107.5
Chronic Treatments
Anticoagulants (%) 5.6 0
ACE Inhibitors (%) 22.2 40.0
Angiotensin Receptor Blockers (%) 22.2 20.0
Statins (%)* 55.6 100
Aspirin (%)*
a 22.2 90.0
Clopidogrel (%) 11.1 10.0
Other antiaggregants (%) 11.1 0.0
Other
Echocardiography (%) 88.9 100
Coronariography (%) 94.4 100
One or two vessel disease (%) 78.6 100
Left Descending Artery disease (%) 50.0 44.4
Left Main Artery disease (%) 6.7 11.1
PTCA (%) 58.8 88.9
CABG (%) 11.1 0
Hx: history of; ACE: angiotensin converting enzyme; PTCA: percutaneous transluminal coronary angioplasty; CABG: coronary artery by-pass grafting.
*p,0.05;
athe proportion of SCAD patients with aspirin treatment was chosen to match the NSTE-ACS group at the moment the sample was taken: overall, 83.3% of ACS patients
were given aspirin before blood collection (22.2% were already having aspirin before being taken to hospital).
doi:10.1371/journal.pone.0013404.t001
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shown to interact with SPARC (Secreted Protein Acidic and Rich in
Cysteine) (Fig. 3). In addition, five proteins are known to be involved
in the GPVI signaling cascade, as demonstrated by a recent
phosphoproteomics study of GPVI-activated platelets [11]:
a-actinin-1, FYB, ILK, and Src (common to aIIbb3 signaling),
plus myosin-9.
A selection of the above proteins was validated by 1D and 2D
western blotting. We chose two signaling proteins, Src and ILK,
and a secreted one, SPARC. No statistically significant differences
were observed for Src and ILK by western blot from 1D gels (data
not shown). As it can be appreciated by 2D-western blotting,
differences related to Src and ILK were on variants originated
following post-translational modifications (PTMs), quite common
in these signaling proteins after platelet activation: phosphoryla-
tion in the case of Src, and proteolysis in the case of ILK (Figure 4).
Interestingly, the two ILK spots identified corresponded to N-
terminal proteolytic fragments of the protein (Figure 4 and Table
S1). A theoretical calculation of pI and molecular weigh on the
ExPASy proteomics server (http://www.expasy.org) gave for an
ILK N-terminal fragment of 165 amino acids – which is the length
comprising the peptides identified by MS – values of 18618.10 Da
and pI of 5.95, which are very close to the experimental values
obtained in our analysis (Table S1). Those values are obviously far
from the theoretical ones for ILK: 51419 Da and pI of 8.30. ILK
spots on that range were not detected because the analysis focused
on the pI 4–7 range. In the case of Src, the differentially regulated
protein feature identified has an experimental pI of 6.0, when the
theoretical one is of 7.10 (Table S1), which is consistent with a
phosphorylated form.
Platelet-secreted protein SPARC is down-regulated in
platelets from NSTE-ACS patients
In the proteomic analysis, SPARC was detected in one spot
down-regulated in platelets from NSTE-ACS patients. Samples
obtained during follow-up revealed that significant differences
between acute and stable patients disappeared already at day 5
after the acute event (Figure 5A). Western blot analysis of
intracellular SPARC following 1D-SDS PAGE confirmed the
proteomics results (Figure 5B). This down-regulation could be due
to a secretion process, given the limited protein synthesis capacity
of platelets [20]. In this context, preliminary studies on platelet-
poor plasma (PPP) from NSTE-ACS patients, compared to
matched chronic controls, suggest that circulating SPARC levels
are increased in NSTE-ACS patients (not shown).
Discussion
The present study demonstrates for the first time that platelets
from NSTE-ACS patients express a characteristic 2-DE-based
proteomic profile during the acute phase compared to platelets
from SCAD matched controls, involving a significant number of
proteins implicated in platelet signaling. The significant presence
of interconnected cytoskeletal, signaling, and secreted proteins
among the variants is in agreement with the notion of increased
platelet activation in the NSTE-ACS patients in parallel to the
Figure 1. High-resolution 2-DE-based proteome analysis of platelets from NSTE-ACS patients. Representative 2-DE gel image of
circulating platelets (IEF: 4–7 pH range; second dimension: 10%SDS-PAGE). The figure shows the location on the 2D gels of those spots differentially
regulated when comparing NSTE-ACS patients and SCAD controls. Protein identifications are shown by the identification numbers in Table 2. Further
information can be found in Table S1.
doi:10.1371/journal.pone.0013404.g001
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patients were confirmed not only by their comparison with a
control SCAD group, but also by a prospective re-evaluation in
sequential visits during 6-month follow-up.
Platelets are implicated in the initiation, development and total
extent of myocardial damage during an acute event [21].
Moreover, there is no doubt platelets play a fundamental role in
the thrombus formation that follows the atheroma plaque rupture
and leads to an ACS. Indeed, a few platelet-activation markers
have been associated with ACS. That is the case of the platelet
surface P-selectin or CD40 ligand (CD40-L or CD154) [22]. A
recent study has shown patients with acute myocardial infarction
(MI) and unstable angina have higher levels of platelet CD154 and
P-selectin as compared to those with stable angina or healthy
Table 2. Platelet proteins differentially regulated in NSTE-ACS versus SCAD patients.
Function Protein Uniprot Code Spot Fold change
Cytoskeletal Actin Cytoplasmatic-1 ACTB_HUMAN 925 +1.71
Alpha-actinin-1 ACTN1_HUMAN 450 +1.63
Caldesmon CALD1_HUMAN 2818 +2.25
F-actin-capping protein subunit beta CAPZB_HUMAN 1083 22.04
Filamin-A FLNA_HUMAN 1311 21.62
1322 22.86*
1626 21.69*
1631 22.02*
1856 +2.16
Myosin-9 MYH9_HUMAN 885 21.86
Talin-1 TLN1_HUMAN 414 21.97
639 22.26
798 22.15*
905 22.48*
1169 21.67*
1184 +3.36*
1186 21.59*
1254 22.07*
1557 21.70*
1614 +2.60*
Tropomyosin alpha chain 3 TPM3_HUMAN 299 23.90*
Zyxin ZYX_HUMAN 602 +1.93*
Signaling Adenylyl cyclase-associated protein 1 CAP1_HUMAN 2062 21.73
FYN-binding protein(ADAP, SLAP-130) FYB_HUMAN 1148 21.98
Integrin-linked protein kinase ILK_HUMAN 1836 21.70
2076 21.92
Proto-oncogene tyrosine-protein kinase Src SRC_HUMAN 1935 21.57
Rho GDP-dissociation inhibitor 2 GDIR2_HUMAN 1833 21.54
Extracellular Serum Albumin ALBU_HUMAN 1284 +1.85
1670 +2.20
2337 21.64
SPARC (Secreted protein acidic and rich in cysteine) SPRC_HUMAN 225 22.13*
Vesicles/Secretory trafficking pathway Dynamin-1-like protein DNM1L_HUMAN 1925 21.98*
Ras-related protein Rab-27B RB27B_HUMAN 713 21.66
Ras-related protein Rab-6B RAB6B_HUMAN 1131 21.91*
1504 21.54
Ras-related protein Rab-11A RB11A_HUMAN 1501 21.57*
1818 21.64
Miscellaneous MAPRE-1 (Microtubule-associated protein RP/EB family
member 1)
MARE1_HUMAN 653 +2.06*
Septin-11 SEP11_HUMAN 1913 22.05*
Differentially regulated features have a p,0.05 except those marked with an asterisk, which have a p,0.01. A negative fold change indicates the protein feature is
down-regulated in NSTE-ACS whereas a positive fold change indicates the spot is up-regulated in the acute group.
doi:10.1371/journal.pone.0013404.t002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13404Figure 2. Selection of proteins differentially regulated between NSTE-ACS and SCAD patients. Enlargement of representative spots for
(A) Talin-1 (spot No. 1557), (B) ILK (spot No. 2076), (C) Src (spot No. 1935), and (D) FYB (spot No. 1148). Panel i) shows representative 2-DE images;
panel ii) shows a bar graph for each spot showing variations in mean volume 6 SD in different groups: SCAD (n=10), and NSTE-ACS (n=18) on
admission, day 5, and 6 months after the acute event. * indicates higher expression of the highlighted protein in the referred group of patients.
doi:10.1371/journal.pone.0013404.g002
Platelet Proteomics of ACS
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13404volunteers [23]. Nevertheless, the more direct, biology-based
approach to platelet biomarkers may rest with an ability to
characterize them in either a state of interaction with other cells
(e.g. platelet-leukocyte aggregates) or transformation (e.g. micro-
particles), or by analyzing protein/mRNA expression (by proteo-
mics and transcriptomics) [22]. In this context, our study tried to
pioneer the application of platelet proteomics to the study of ACS
with the aim of improving our knowledge on the protein changes
that happen in platelets in parallel to the onset of the acute event.
We focused our efforts on NSTE-ACS, which is generally
associated with white, platelet-rich, and only partially occlusive
thrombus, which cause minimal myocardial necrosis [1].
Eighty-five per cent of the platelet proteome is within the 4–7 pI
range when separated by 2-DE [24], so we decided to focus on
that range. The use of large zoom gels and a very sensitive
fluorescent dye allowed the detection of over 2,200 proteins per
gel. Following our proteomic analysis, we found 40 protein spots to
be differentially regulated between platelets from NSTE-ACS and
SCAD patients. The fact those spots were related to 22 unique
genes suggests some cases of extensive PTMs, quite common in
platelets following activation, such as phosphorylations or natural
proteolysis. A good example to illustrate the above is talin-1,
identified in our study in 10 spots. The NetPhos 2.0 server
(Technical University of Denmark, Lyngby, Denmark) predicts a
total number of 111 theoretical phosphorylation sites for talin [25].
Phosphorylation of some of those sites and dephosphorylation of
others, following platelet activation, could explain the amount of
talin features found in the present study with similar molecular
weigh and different pI. Regarding the discrepancy between the
theoretical molecular mass of talin-1 (269,718 Da) and the in-gel
mass, the reason is natural proteolysis by calpain [26].
Involvement of signaling proteins
It is noteworthy that most of the proteins identified in the
present study are interconnected in a common network that
primarily involves cytoskeletal and signaling proteins. Platelet
Figure 3. Analysis of differentially regulated proteins by Ingenuity Pathways Analysis software (Ingenuity Systems, CA). Potential
protein interactions are shown in the following network: Cellular assembly and organization, cell morphology, and cellular development. Proteins
identified by differential analysis are shown as shaded nodes with their gene names. Solid lines represent direct interactions, dotted represent
indirect interactions. Arrows from one node to another indicate that this node acts upon the other. Lines without arrows represent binding. Node
shapes are: Double circle=complex or group; notched triangle=kinase; wavy shape=enzyme; circle=other. Proteins known to be involved in
platelet activation by aIIbb3 and/or GPVI are indicated with a black solid arrow.
doi:10.1371/journal.pone.0013404.g003
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that induce outside-in signaling resulting in intracellular phos-
phorylation, inside-out signaling, cytoskeleton reorganization and
granules secretion. This eventually leads to platelet adhesion and
aggregation, and thrombus formation. Two of the main platelet
receptors are GPVI and the integrin aIIbb3. GPVI is the main
signaling receptor for collagen whereas aIIbb3 interacts with
fibrinogen and is the main responsible for platelet aggregation.
Interestingly, an important number of the differentially regulated
proteins identified in our study are known to be phosphorylated in
response to platelet activation by GPVI and aIIbb3 [11,12]. Both
receptors share some similarities in the initiation of their signaling
cascades, where Src family kinases (SFKs) play a major role.
Outside-in signaling by aIIbb3 is positively regulated by talin,
which physically binds to the b3 tail through a phosphotyrosine
binding domain (PTB) [19], and Src [12]. Both Src and talin were
identified in our study.
In platelets, ILK contributes to inside-out integrin activation
[27], and participates in a ternary complex – together with
particularly interesting new Cys-His protein (PINCH) and parvin – that
functions as a signaling platform for integrins [28]. ILK not only
controls integrity affinity but is also required for a-granule
secretion, and therefore may play a central role in the regulation
of platelet function [18]. Interestingly, we describe here for the first
time the identification of N-terminal proteolytic fragments of ILK
containing the PINCH binding domain. This opens new windows
for future functional studies related to platelet activation by
receptors, such as the integrin aIIbb3, where ILK plays a major
role.
Secreted proteins: SPARC
An important event associated with platelet activation is the
release of proteins. In our analysis we identified several proteins
either secreted or involved in secretory trafficking pathways. In
addition, platelet activation is associated with an increase in the
release of microparticles (MPs). Indeed, increased numbers of
circulating MPs have been reported in patients with ACS [29],
and platelet-derived MPs have been shown to induce angiogenesis
and improve revascularization after chronic ischemia in vivo [30].
Interestingly, 91% of the proteins identified in our study have been
reported to be present in platelet MPs [31,32], and 50% in the
platelet releasate [31]. We hypothesize that some of those proteins
could be released from the activated platelets either by direct
secretion or as a part of MPs. The limited protein synthesis
capacity of platelets [20] could explain why some of those proteins
(e.g. SPARC) are down-regulated in NSTE-ACS patients.
As mentioned above, one of the secreted proteins identified in
our study was SPARC, which is primarily released from a-
granules following platelet activation [33] and is also present in
platelet MPs [31]. SPARC is a matricellular glycoprotein
transiently induced in the infarct, regulating cellular interactions
and promoting matrix assembly. It is also involved in wound
healing by the facilitation of angiogenesis [34]. Recent studies have
shown that local production of SPARC is essential for mainte-
nance of the integrity of cardiac ECM after MI, emphasizing the
potential therapeutic application of this protein to prevent cardiac
dilatation and dysfunction after MI [35]. Interestingly, SPARC
regulates ECM organization through its modulation of ILK
activity [36]. On the other hand, in vascular endothelial cells
exogenous SPARC facilitates endothelial permeability resulting in
barrier dysfunction. Indeed, SPARC has been observed in
atherosclerotic regions, and SPARC plasma levels were found to
be elevated in obesity and CAD patients [37]. The possibility that
SPARC may be ectopically expressed in those patients, such as in
the activated platelets, cannot be excluded [37]. Our data suggest
a higher platelet secretion of SPARC in NSTE-ACS patients.
Further research is on the way with plasma samples from a larger
number of patients and controls to confirm this hypothesis. In that
case, it would be also of interest to explore whether platelets
release SPARC just after or before the acute event, which could be
related to its primary physiological role in the disease.
Study limitations
The study presents some limitations that should be taken in
mind. Ideally, NSTE-ACS patients entering the study should have
been with no drug therapy that could interfere with the analysis so
the control group would have been healthy subjects; however that
was not feasible for obvious reasons. In order to compensate for
Figure 4. ILK and Src are differentially regulated in NSTE-ACS versus SCAD platelets due to PTMs. Differentially regulated protein
features corresponding to ILK and Src are highlighted in 2D-western blot images representative of the results obtained for the patients included in
the study. Membranes were probed with mouse antibodies against ILK, and Src.
doi:10.1371/journal.pone.0013404.g004
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matched in the best possible way to the acute group. Secondly, the
small volume of blood available per patient did not allow running
a higher number of gels and to cover more basic pI ranges in the
2-DE analysis, so some additional differences could have been
missed. In addition, there are limitations inherent to 2-DE, such as
the potential under-representation of very hydrophobic proteins.
Sample limitation was also an impediment to do further functional
analyses related to the proteins identified; more samples will be
needed to do so. Further characterization of the platelet proteome,
focusing on additional subgroups of ACS patients, will likely
increase our understanding of platelet functions in ACS.
Conclusions
This study provides novel information on platelet protein
changes associated to NSTE-ACS and shows proteomics can be
used to follow platelet proteome changes during the disease follow-
up. The proteomic analysis identified several differentially
regulated proteins integrated in a common network linked to
changes in cell morphology. Several of those proteins are involved
in signal transduction; indeed some are known to participate in
aIIbb3 and GPVI signaling, which suggests these pathways may
play a relevant role in platelet activation associated with NSTE-
ACS. Interestingly, the levels of platelet-secreted glycoprotein
SPARC were decreased in platelets from NSTE-ACS patients as
Figure 5. SPARC is down-regulated in platelets from NSTE-ACS patients. A) 2-DE proteomics data. Panel i) shows representative 2-DE
images for SPARC; panel ii) presents a bar graph showing variations in mean volume 6 SD corresponding to SPARC spots in different groups: SCAD
(n=10), and NSTE-ACS (n=18) on admission, day 5, and 6 months after the acute event. B) Western blotting data. i) Western blot analysis of SPARC
(upper panel) and b-actin (lower panel) protein expression levels in platelets from NSTE-ACS and SCAD patients. Images are representative of the
results obtained for all the patients included in the study. ii) Densitometry graph representing the mean values 6 SD of band intensities
corresponding to SPARC expression assessed by western blot, with respect to b-actin. Experiments were done in duplicate.
doi:10.1371/journal.pone.0013404.g005
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secretion associated to platelet activation in NSTE-ACS. Our
results, if confirmed in larger studies, open a field for future
investigation on novel therapeutic targets in ACS.
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